🫠 This Week in Psychedelics

Welcome to Tricycle Day. We’re the psychedelics newsletter that conspires with the universe to bring you hope and the occasional snort-laugh. It’s a solid partnership.

Here’s what we got this week.

We just added more dates for our most popular experience.

At $750, Althea’s Pick is the most affordable way to have a legal psilocybin journey with a licensed facilitator.

Every booking includes the journey itself, plus prep and integration support, because that's how this work should be done.

FYI, the facilitators leading these groups are some of the most sought-after in the space. We're not cutting corners or asking you to compromise on quality.

There's one spot left for the July 24th group in Portland. Book it by July 20 and it's yours for $600 instead of $750.

Equal-opportunity empathogen: MDMA-assisted therapy may alleviate discrimination-related trauma in marginalized populations.
The good life: DMT produced sustained improvements in life satisfaction and quality of life in patients with depression.
Twinning: Based on a study of twins, psychedelic use may be linked to a significantly lower likelihood of migraines.
Straight no chaser: Psychedelics show potential as treatments for the neural and behavioral dysfunctions of fetal alcohol syndrome.
Now recruiting: A firefighter and CIIS student is investigating whether first responders’ use of psychedelics shapes their sleep quality, burnout, and recovery.

State of play: In its Q2 psychedelic policy briefing, MAPS highlights momentum across three states and at the federal level.
Who’s next? Minnesota is on the verge of expanding access to psychedelic therapy.
The dog ate their homework: Senators are pressing the DOJ to explain why it missed its deadline to clear the way for more psychedelic research.
It’s wild out here: The FDA is cracking down on illicit online ketamine sellers.

Buy low, get high: The Motley Fool rounds up its five best psychedelics stocks for 2026.
Ride the wave: Psychedelics are surging again after the latest data dumps from Compass and Definium.
Property of: Clearmind Medicine is collecting patents to protect its pipeline of treatments for binge behaviors.
Free the data: MAPS released an open-access ibogaine investigator’s brochure to make sure research isn’t limited just to pharmaceutical companies.
Integration, on the house: Nectara is becoming a non profit and making its platform free for all users.

Dante’s inferno: A documentary premiering this month follows a Colorado man’s 500-mile run on psychedelics. (See previous coverage.)
Spice rack: The newest Dune movie was filmed with a dedicated “psychedelic unit.”
Anything is possible: Someone used a Game Boy to photograph the planet Jupiter.
Meme of the week: Cult leaders will post up outside the psychedelic treatment center like…

We usually don’t get sucked into conspiracy theories. But c'mon.

This many federal agencies do not coordinate their psychedelics announcements by accident. Someone's got a Signal chat we don't know about.

On Monday, the FDA, HHS, VA, NIDA, and ARPA-H all dropped psychedelics-related news within hours of each other.

Maybe it’s a ripple effect of Trump’s executive order, or maybe the feds all came to their senses independently. (Doubt it.) Either way, Washington is officially locked in on psychedelics.

Here's the rundown of what’s already happened this week.

To be fair, none of this changes anything for patients today. But why would you build this much infrastructure unless you planned on using it?

It’s getting real, Cyclists. If this is what happens when secret power networks meet in the shadows to bend reality toward their will, then sign us up for the psyop.

Bout time the deep state got its priorities straight. 🫠

Two years ago, Massachusetts almost legalized psychedelics, but the yeas got edged out by the nays at the ballot box. Now, it looks like the legislature might go where voters wouldn’t. Lawmakers just tucked a five-year psychedelic therapy pilot into a big economic development bill, which would let up to three licensed mental health clinics administer naturally occurring psychedelics to “clinically appropriate patients” under strict supervision.

Yes, the guardrails are much tighter than Question 4’s decrim agenda. But clinical doesn’t have to mean corporate. Grassroots activists left their fingerprints all over this thing. First of all, cannabis and pharmaceutical companies are explicitly barred from running these clinics. Second, the bill creates a Medical Psychedelics Fund, modeled on New Mexico's equity program, meant to keep the treatment accessible to low-income patients.

Speaking of corporate interests, we know Compass Pathways (the frontrunner in the psychedelic pharma race) has spent a pretty penny lobbying Beacon Hill anyway. The fact that this measure is advancing, even with Compass’s synthetic psilocybin likely months away from FDA approval, suggests there’s still appetite for the whole mushroom in all its glory.

Here’s a not-so-fun fact. The psychiatric condition with the highest mortality rate isn’t depression or PTSD. It’s actually anorexia nervosa (though you’d never guess it from the airtime it gets in mental health conversations). This week, the deadly disease is getting its turn in the spotlight, after a new pilot study found that psilocybin can help, even in the most treatment-resistant cases.

21 women, whose illness had lasted on average 11 years, went through three dosing sessions over six weeks alongside their existing care. The first win was that 95.2% completed treatment at all. (Dropout is a major issue in this condition.) Eating disorder severity scores also fell significantly, with 47.6% of participants landing within the “community norm” range by the three-month mark. That’s effectively remission, according to the researchers. Their motivation to pursue recovery also kept climbing for a full year afterward.

Safety-wise, most side effects were mild. But one participant did attempt suicide twice, months after the sessions wrapped. Fwiw, the researchers don’t blame the psilocybin. (Deadly disease, remember?) Of course, we’re dealing with a small study with big limitations. We just hope these findings get people talking… and eating. Mushrooms, to start.

That’s all for today, Cyclists! Whenever you’re ready, here’s how we can help.

Forwarded this email? Subscribe here.

DISCLAIMER: This newsletter is for educational and informational purposes only and is not intended as a substitute for professional medical advice. The use, possession, and distribution of psychedelic drugs are illegal in most countries and may result in criminal prosecution.